Johnson & Johnson Vision Acuvue TheravisionJohnson & Johnson Vision announced today that it received FDA approval for its Acuvue Theravision with Ketotifen.

The eye health business arm of Johnson & Johnson (NYSE:JNJ) designed Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen) to provide a new wearing experience for contact lens wearers who have allergic eye itch for up to 12 hours without the need for allergy drops while also providing vision correction.

Get the full story at our sister site, Drug Delivery Business News.